399 related articles for article (PubMed ID: 21375481)
21. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease.
Matsuo K; Okamoto H; Kawai Y; Quan YS; Kamiyama F; Hirobe S; Okada N; Nakagawa S
J Neuroimmunol; 2014 Jan; 266(1-2):1-11. PubMed ID: 24315156
[TBL] [Abstract][Full Text] [Related]
22. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
Herline K; Drummond E; Wisniewski T
Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
[TBL] [Abstract][Full Text] [Related]
23. Validating Immunotherapy in Alzheimer's Disease: The EB101 Vaccine.
Carrera I; Fernandez-Novoa L; Aliev G; Vigo C; Cacabelos R
Curr Pharm Des; 2016; 22(7):849-58. PubMed ID: 26648469
[TBL] [Abstract][Full Text] [Related]
24. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
[TBL] [Abstract][Full Text] [Related]
25. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.
Kim HD; Jin JJ; Maxwell JA; Fukuchi K
Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533
[TBL] [Abstract][Full Text] [Related]
26. Vaccination strategies for Alzheimer's disease: A new hope?
Woodhouse A; Dickson TC; Vickers JC
Drugs Aging; 2007; 24(2):107-19. PubMed ID: 17313199
[TBL] [Abstract][Full Text] [Related]
27. Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant.
Yu YZ; Wang S; Bai JY; Zhao M; Chen A; Wang WB; Chang Q; Liu S; Qiu WY; Pang XB; Xu Q; Sun ZW
Clin Immunol; 2013 Oct; 149(1):11-24. PubMed ID: 23886550
[TBL] [Abstract][Full Text] [Related]
28. Vaccines for Alzheimer's disease: how close are we?
Janus C
CNS Drugs; 2003; 17(7):457-74. PubMed ID: 12751917
[TBL] [Abstract][Full Text] [Related]
29. Recent advance in immunotherapies for Alzheimer disease: with special reference to DNA vaccination.
Okura Y; Matsumoto Y
Hum Vaccin; 2009 Jun; 5(6):373-80. PubMed ID: 19221518
[TBL] [Abstract][Full Text] [Related]
30. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies.
Tabira T
Tohoku J Exp Med; 2010 Feb; 220(2):95-106. PubMed ID: 20139660
[TBL] [Abstract][Full Text] [Related]
31. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.
Cribbs DH; Agadjanyan MG
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):82-7. PubMed ID: 19355929
[No Abstract] [Full Text] [Related]
32. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
[TBL] [Abstract][Full Text] [Related]
33. [Immunotherapy for Alzheimer's disease targeting Aβ].
Tabira T
Nihon Rinsho; 2016 Mar; 74(3):423-6. PubMed ID: 27025080
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
Blennow K; Hampel H; Zetterberg H
Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
[TBL] [Abstract][Full Text] [Related]
35. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
Pride M; Seubert P; Grundman M; Hagen M; Eldridge J; Black RS
Neurodegener Dis; 2008; 5(3-4):194-6. PubMed ID: 18322388
[TBL] [Abstract][Full Text] [Related]
36. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
Delrieu J; Ousset PJ; Caillaud C; Vellas B
J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
[TBL] [Abstract][Full Text] [Related]
37. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?
Lemere CA; Masliah E
Nat Rev Neurol; 2010 Feb; 6(2):108-19. PubMed ID: 20140000
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease.
Minami SS; Sidahmed E; Aid S; Shimoji M; Niikura T; Mocchetti I; Rebeck GW; Prendergast JS; Dealwis C; Wetzel R; Bosetti F; Matsuoka Y; Hoe HS; Turner RS
J Neuroinflammation; 2010 Sep; 7():57. PubMed ID: 20920207
[TBL] [Abstract][Full Text] [Related]
39. [Novel vaccine therapy for Alzheimer's disease--recent progress and our approach].
Okura Y; Matsumoto Y
Brain Nerve; 2008 Aug; 60(8):931-40. PubMed ID: 18717197
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for Alzheimer's disease.
Solomon B; Frenkel D
Neuropharmacology; 2010; 59(4-5):303-9. PubMed ID: 20388523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
